Dose-Escalation Study Of SB-485232 Administered As Daily Subcutaneous Injections In Adults With Solid Tumors

This study has been completed.
Sponsor:
Information provided by:
GlaxoSmithKline
ClinicalTrials.gov Identifier:
NCT00085878
First received: June 16, 2004
Last updated: October 15, 2008
Last verified: October 2008
  Purpose

This is a phase I, open-label, dose-escalation study of SB-485232. Subjects will receive SB-485232 administered as subcutaneous injections daily for 14 days. Dose escalation (enrollment into the next cohort) cannot occur until all three subjects have completed the previous cohort; 5 doses will be tested. An additional dosing regimen has been added to evaluate higher doses given twice weekly for 7 weeks. Therefore, the full evaluation period for each patient will extend out to approximately eleven weeks after the first day of SB-485232 dosing.


Condition Intervention Phase
Solid Tumor Cancer
Drug: SB-485232
Phase 1

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Endpoint Classification: Safety Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: A Phase I, Dose Escalation Study to Assess the Safety and Pharmacokinetics of SB- 485232 Administered as Daily Subcutaneous Injections in Adult Patients With Solid Tumors

Resource links provided by NLM:


Further study details as provided by GlaxoSmithKline:

Primary Outcome Measures:
  • - Safety and tolerability endpoints will include evaluation of adverse events and changes in laboratory values and clinical variables from pre-dose values. [ Time Frame: 11 Weeks ]

Secondary Outcome Measures:
  • - Biologically effective dose based. - Pharmacokinetic endpoints: AUC, Adverse Events, cmax, tmax, and t1/2. - Presence or absence of anti-SB-485232 antibodies. - Pharmacodynamic endpoints. - Radiographic tumor assessments. [ Time Frame: 11 Weeks ]

Enrollment: 25
Study Start Date: January 2003
Intervention Details:
    Drug: SB-485232
    Other Name: SB-485232
  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Histologically or cytologically confirmed diagnosis of malignancy.
  • Subjects with solid tumors must have locally advanced or metastatic disease at the time of enrollment.
  • Measurable or evaluable disease that is refractory or resistant to standard therapy or for which there is no effective standard therapy.
  • Predicted life expectancy of at least 12 weeks.
  • Kinesin spindle protein (KPS) of greater than 70%.
  • No chemotherapy, immunotherapy, hormonal therapy, or biological therapy for cancer, radiotherapy, or surgical procedures (except for minor surgical procedures) within 4 weeks before beginning treatment with SB-485232 (6 weeks for nitrosoureas and mitomycin C).
  • Subjects must have recovered from toxicities (incurred as a result of previous therapy) sufficiently to be entered into a Phase I study.
  • Provide written informed consent.
  • Absence of anti-SB-485232 antibodies.
  • Hemoglobin greater than or equal to 9 g/dL.
  • Absolute neutrophil count greater than or equal to 1.5 X 109 /L.
  • Platelet count greater than or equal to 100 X 109 /L.
  • Partial thromboplastin time (PTT) and prothrombin time/international normalized ratio (PT/INR) within normal limits.
  • Serum creatinine less than or equal to 1.5 mg/dL (135 µmol/L) or estimated creatinine clearance greater than 50 mL/min (calculated by the Cockcroft-Gault Formula).
  • Total serum bilirubin less than or equal to 1.5 mg/dL.
  • Aspartate transaminase (AST) and alanine transaminase (ALT) less than or equal to 3 X ULN.
  • Sexually active males or females of reproductive capacity must use adequate contraception.
  • For subjects with a history of coronary artery disease, stress test must be within normal limits.
  • Subjects with a history of congestive heart failure, myocardial infarction or prior anthracycline chemotherapy must have a Multiple Gated Acquisition (MUGA) scan with a left ventricular ejection fraction of greater than 40%.

Exclusion Criteria:

  • Women who are pregnant or are breast-feeding.
  • Severe or uncontrolled infections requiring systemic antibiotic therapy.
  • Any serious medical or psychiatric disorder that would interfere with subject safety or informed consent.
  • Known leptomeningeal disease or evidence of prior or current metastatic brain disease.
  • Receiving concurrent chemotherapy, immunotherapy, radiotherapy, or investigational therapy.
  • Receiving concurrent systemic steroids.
  • History of ventricular arrhythmias requiring drug or device therapy.
  • Any severe concurrent disease or condition, including significant autoimmune diseases, which in the judgment of the principal investigator, would make the subject inappropriate for study participation.
  • Any unresolved or unstable serious toxicity from prior administration of another investigational drug.
  • Any investigational drug within 30 days or 5 half-lives (whichever is longer) preceding the first dose of SB-485232.
  • Psychological, familial, sociological, or geographical conditions that do not permit compliance with the study.
  • Received prior treatment with SB-485232.
  • Poor venous access.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00085878

Locations
United States, California
GSK Investigational Site
Santa Monica, California, United States, 90404-2104
United States, Indiana
GSK Investigational Site
Indianapolis, Indiana, United States, 46202
United States, North Carolina
GSK Investigational Site
Durham, North Carolina, United States, 27705
United States, Pennsylvania
GSK Investigational Site
Philadelphia, Pennsylvania, United States, 19111
Sponsors and Collaborators
GlaxoSmithKline
Investigators
Study Director: GSK Clinical Trials, MD GlaxoSmithKline
  More Information

No publications provided

Responsible Party: Study Director, GSK
ClinicalTrials.gov Identifier: NCT00085878     History of Changes
Other Study ID Numbers: 485232/002, 002
Study First Received: June 16, 2004
Last Updated: October 15, 2008
Health Authority: United States: Food and Drug Administration

Keywords provided by GlaxoSmithKline:
IL-18
subcutaneous
pharmacokinetics
Phase 1

Additional relevant MeSH terms:
Neoplasms

ClinicalTrials.gov processed this record on September 30, 2014